102 However, numerous groups are advocating to the incorporation of novel markers, like a complicated karyotype55 or epigenetic subsets, 27,28 into clinical practice. All these novel prognostic and/or predictive products will must be validated in cohorts of sufferers addressed with focused brokers.Very well this is embarassing! Our site encountered